Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | afamitresgene autoleucel |
Trade Name | Tecelra |
Synonyms | MAGE-A4 SPEAR T cells|MAGE-A4C1032T|ADP-A2M4 cells|afami-cel |
Drug Descriptions |
Tecelra (afamitresgene autoleucel) are autologous T-cells that are modified to express a T-cell receptor that recognizes the human melanoma antigen 4 (MAGE-A4) peptide region from 230-239, which potentially inhibits growth of MAGE-A4-expressing tumor cells (PMID: 32002290). Tecelra (afamitresgene autoleucel) is FDA-approved for use in patients with MAGE-A4-positive unresectable or metastatic synovial sarcoma who have received prior chemotherapy, and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive (FDA.gov). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C138107 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
afamitresgene autoleucel | afamitresgene autoleucel | 0 | 3 |
afamitresgene autoleucel + Nivolumab | Nivolumab afamitresgene autoleucel | 0 | 1 |
afamitresgene autoleucel + Pembrolizumab | Pembrolizumab afamitresgene autoleucel | 0 | 1 |